New drug combo aims to stop advanced cervical cancer from returning
NCT ID NCT07368985
First seen Jan 27, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tests whether adding two drugs, pembrolizumab and lenvatinib, to standard chemoradiation can keep high-risk cervical cancer from coming back. About 87 adults with advanced cervical cancer will receive the drugs alongside radiation and brachytherapy. The main goal is to see if this combination improves the time people live without their cancer worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER BY FIGO STAGE 2018 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Erasmus MC
Rotterdam, South Holland, 3015 GD, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.